Literature DB >> 31625605

Use of medication for attention-deficit/hyperactivity disorder and risk of unintentional injuries in children and adolescents with co-occurring neurodevelopmental disorders.

Laura Ghirardi1, Qi Chen1, Zheng Chang1, Ralf Kuja-Halkola1, Charlotte Skoglund2, Patrick D Quinn3, Brian M D'Onofrio1,4, Henrik Larsson1,5.   

Abstract

BACKGROUND: Attention-deficit/hyperactivity disorder (ADHD) is often associated with other neurodevelopmental disorders (NDs) and with risky behaviors and adverse health outcomes, including injuries. Treatment with ADHD medication has been associated with reduced risk of injuries. However, it is unknown whether the association is present in individuals with co-occurring NDs. The aim of the present study was to estimate the association between ADHD medication use and unintentional injuries in Sweden in children and adolescents with ADHD, including those with co-occurring NDs.
METHODS: Using a linkage of several national registers via the unique personal identification number, we identified individuals with a diagnosis of ADHD and of other NDs, including autism spectrum disorder, intellectual disability, communication disorders, learning disorders and motor disorders. The primary outcome was unintentional injuries. Secondary outcome was traumatic brain injury (TBI). Individuals were followed from January 1st 2006 or their 5th birthday or the date of the first unintentional injury, whichever came last, to December 31st 2013 or their 18th birthday or death, whichever came first. We compared the rate of injuries during periods on-treatment with the rate of injuries during periods off-treatment within the same individual using stratified Cox regression to calculate hazard ratio (HR) with 95% confidence intervals (CIs).
RESULTS: For children and adolescents with ADHD (N = 9,421) the rate of any unintentional injuries (HR = 0.85; 95% CI = 0.78-0.92) and TBIs (HR = 0.27; 95% CIs = 0.20-0.38) during medicated periods was lower than during non-medicated periods. Similar results were found among individuals with co-occurring NDs (N = 2,986), for unintentional injuries (HR = 0.88; 95% CI = 0.77-1.01) and for TBIs (HR = 0.27; 95% CI = 0.16-0.44).
CONCLUSIONS: Beneficial effects of ADHD medication may extend beyond reduction of ADHD core symptoms to prevention of unintentional injuries in children and adolescents, including individuals with co-occurring NDs.
© 2019 Association for Child and Adolescent Mental Health.

Entities:  

Keywords:  ADHD medication; injuries; neurodevelopmental disorders

Mesh:

Substances:

Year:  2019        PMID: 31625605      PMCID: PMC6980200          DOI: 10.1111/jcpp.13136

Source DB:  PubMed          Journal:  J Child Psychol Psychiatry        ISSN: 0021-9630            Impact factor:   8.982


  46 in total

Review 1.  Research Review: Language problems in children with Attention-Deficit Hyperactivity Disorder - a systematic meta-analytic review.

Authors:  Hannah Korrel; Kathryn L Mueller; Tim Silk; Vicki Anderson; Emma Sciberras
Journal:  J Child Psychol Psychiatry       Date:  2017-02-10       Impact factor: 8.982

2.  Treatment outcomes with methylphenidate formulations among patients with ADHD: retrospective claims analysis of a managed care population.

Authors:  Paul Hodgkins; Rahul Sasané; Laura Christensen; Carolyn Harley; Fang Liu
Journal:  Curr Med Res Opin       Date:  2011       Impact factor: 2.580

Review 3.  Long-Term Outcomes of Attention-Deficit/Hyperactivity Disorder and Conduct Disorder: A Systematic Review and Meta-Analysis.

Authors:  Holly E Erskine; Rosana E Norman; Alize J Ferrari; Gary C K Chan; William E Copeland; Harvey A Whiteford; James G Scott
Journal:  J Am Acad Child Adolesc Psychiatry       Date:  2016-08-04       Impact factor: 8.829

4.  Injury-proneness of youth with attention-deficit hyperactivity disorder: a national clinical data analysis in Taiwan.

Authors:  Yueh-Ming Tai; Susan Shur-Fen Gau; Churn-Shiouh Gau
Journal:  Res Dev Disabil       Date:  2013-01-20

Review 5.  Methylphenidate for children and adolescents with autism spectrum disorder.

Authors:  Nancy Sturman; Laura Deckx; Mieke L van Driel
Journal:  Cochrane Database Syst Rev       Date:  2017-11-21

6.  Serious transport accidents in adults with attention-deficit/hyperactivity disorder and the effect of medication: a population-based study.

Authors:  Zheng Chang; Paul Lichtenstein; Brian M D'Onofrio; Arvid Sjölander; Henrik Larsson
Journal:  JAMA Psychiatry       Date:  2014-03       Impact factor: 21.596

7.  Methylphenidate and the risk of trauma.

Authors:  Kenneth K C Man; Esther W Chan; David Coghill; Ian Douglas; Patrick Ip; Ling-Pong Leung; Matthew S H Tsui; Wilfred H S Wong; Ian C K Wong
Journal:  Pediatrics       Date:  2014-12-15       Impact factor: 7.124

8.  Attention-deficit/hyperactivity disorder and suicide: A systematic review.

Authors:  Judit Balazs; Agnes Kereszteny
Journal:  World J Psychiatry       Date:  2017-03-22

9.  Injury among children and young people with and without attention-deficit hyperactivity disorder in the community: The risk of fractures, thermal injuries, and poisonings.

Authors:  Vibhore Prasad; Joe West; Kapil Sayal; Denise Kendrick
Journal:  Child Care Health Dev       Date:  2018-07-24       Impact factor: 2.508

10.  Drug treatment for attention-deficit/hyperactivity disorder and suicidal behaviour: register based study.

Authors:  Qi Chen; Arvid Sjölander; Bo Runeson; Brian M D'Onofrio; Paul Lichtenstein; Henrik Larsson
Journal:  BMJ       Date:  2014-06-18
View more
  3 in total

Review 1.  The World Federation of ADHD International Consensus Statement: 208 Evidence-based conclusions about the disorder.

Authors:  Stephen V Faraone; Tobias Banaschewski; David Coghill; Yi Zheng; Joseph Biederman; Mark A Bellgrove; Jeffrey H Newcorn; Martin Gignac; Nouf M Al Saud; Iris Manor; Luis Augusto Rohde; Li Yang; Samuele Cortese; Doron Almagor; Mark A Stein; Turki H Albatti; Haya F Aljoudi; Mohammed M J Alqahtani; Philip Asherson; Lukoye Atwoli; Sven Bölte; Jan K Buitelaar; Cleo L Crunelle; David Daley; Søren Dalsgaard; Manfred Döpfner; Stacey Espinet; Michael Fitzgerald; Barbara Franke; Manfred Gerlach; Jan Haavik; Catharina A Hartman; Cynthia M Hartung; Stephen P Hinshaw; Pieter J Hoekstra; Chris Hollis; Scott H Kollins; J J Sandra Kooij; Jonna Kuntsi; Henrik Larsson; Tingyu Li; Jing Liu; Eugene Merzon; Gregory Mattingly; Paulo Mattos; Suzanne McCarthy; Amori Yee Mikami; Brooke S G Molina; Joel T Nigg; Diane Purper-Ouakil; Olayinka O Omigbodun; Guilherme V Polanczyk; Yehuda Pollak; Alison S Poulton; Ravi Philip Rajkumar; Andrew Reding; Andreas Reif; Katya Rubia; Julia Rucklidge; Marcel Romanos; J Antoni Ramos-Quiroga; Arnt Schellekens; Anouk Scheres; Renata Schoeman; Julie B Schweitzer; Henal Shah; Mary V Solanto; Edmund Sonuga-Barke; César Soutullo; Hans-Christoph Steinhausen; James M Swanson; Anita Thapar; Gail Tripp; Geurt van de Glind; Wim van den Brink; Saskia Van der Oord; Andre Venter; Benedetto Vitiello; Susanne Walitza; Yufeng Wang
Journal:  Neurosci Biobehav Rev       Date:  2021-02-04       Impact factor: 9.052

Review 2.  Psychosocial Interventions for Attention Deficit/Hyperactivity Disorder: A Systematic Review and Meta-Analysis by the CADDRA Guidelines Work GROUP.

Authors:  Valerie Tourjman; Gill Louis-Nascan; Ghalib Ahmed; Anaïs DuBow; Hubert Côté; Nadia Daly; George Daoud; Stacey Espinet; Joan Flood; Emilie Gagnier-Marandola; Martin Gignac; Gemma Graziosi; Zeeshan Mansuri; Joseph Sadek
Journal:  Brain Sci       Date:  2022-08-01

3.  Medical disorders in a Danish cohort of children with attention-deficit hyperactivity disorder.

Authors:  Britt Laugesen; Marlene Briciet Lauritsen; Emil Færk; Christina Mohr-Jensen
Journal:  Eur Child Adolesc Psychiatry       Date:  2021-01-02       Impact factor: 4.785

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.